...
Dryness & GSM faq

Moisturiser vs lubricant—what’s the difference and when to use each?

Think “daily hydration” versus “on-the-day glide.” Vaginal moisturisers are used several times weekly to rehydrate tissue between applications and reduce day-to-day friction. Lubricants are used just before intimacy, examinations or dilator work to reduce shear forces in the moment. Many people with genitourinary syndrome of menopause (GSM) use both. Choose gentle, fragrance-free products and tailor to your needs. Educational only. Results vary. Not a cure.

Clinical Context

Who suits moisturisers most? Anyone with persistent background dryness, a sandpaper-like sensation on walks/cycling, or stinging with urine on delicate skin. They’re helpful while awaiting review, for people avoiding hormones, and as a base even when local therapies are added later.

Who relies more on lubricants? Those whose main issue is situational friction—during sex, examinations, or dilator therapy. A silicone-based lubricant can help when arousal lubrication is limited; water-based options are versatile and condom-friendly; oil-based feel rich but may not be compatible with latex.

When to escalate or adapt. If penetration is sharp or burning at the entrance despite good lubrication, consider pelvic floor over-activity or vestibulodynia—pelvic health physiotherapy and paced, comfort-first intimacy often help. If moisturiser + lubricant are insufficient, local oestrogen or DHEA may be added after assessment. Review in 6–12 weeks to fine-tune to the lowest effective maintenance.

Evidence-Based Approaches

UK guidance supports starting with non-hormonal measures and escalating as needed. The NICE menopause guideline (NG23) recommends information on vaginal moisturisers and lubricants and considering low-dose local vaginal oestrogen when GSM affects quality of life. Patient-facing advice from the NHS on vaginal dryness offers practical self-care and red-flag symptoms.

Randomised trials summarised in the Cochrane Library indicate that local oestrogens improve dryness, soreness, dyspareunia and pH versus placebo across formulations, with low systemic absorption at licensed doses. Prescribers and informed patients can use the BNF for UK product details, cautions and interactions.

Peer-reviewed overviews indexed on PubMed describe GSM mechanisms (thinner epithelium, raised pH, lactobacilli loss) and where moisturisers, lubricants, vaginal DHEA and pelvic floor/psychosexual approaches fit. Together, these sources support a practical plan: schedule a moisturiser; add a compatible lubricant for higher-friction moments; escalate to local therapy if needed; and tailor adjuncts (physiotherapy, psychosexual support) to restore comfort and confidence.